G
Guangzhou Zhiyi Biotechnology
Focuses on the research and development of second-generation probiotics and Live Biotherapeutics
About Guangzhou Zhiyi Biotechnology
Guangzhou Zhiyi Biotechnology Co., Ltd., established in 2013, operates as a clinical-stage biopharmaceutical company focused on the development of Live Biotherapeutic Products (LBPs) and next-generation probiotics. The company was co-founded by Dr. Zifachao, a prominent expert in digestive diseases, and Liu Yangyang, whose doctoral research on a specific strain of Bacteroides fragilis, named SK08, laid the foundational science for the company. This initial discovery highlighted the potential of the bacterium in treating digestive disorders.
The firm has strategically positioned itself in the emerging field of microbiome-based therapeutics, building a comprehensive platform that spans from the initial discovery of novel functional bacterial strains to late-stage clinical development and commercial-scale manufacturing. This integrated system allows for research into the relationship between the human microbiome and diseases, target identification, and the subsequent development of LBP candidates. The company's business model is centered on the research, development, and eventual commercialization of proprietary microbial-based drugs and also encompasses a business segment for health foods and ordinary foods.
Zhiyi Biotechnology's lead product candidate, SK08, is a live biotherapeutic developed from a proprietary strain of *Bacteroides fragilis*. This product is notable for being China's first domestically developed LBP to enter clinical trials. SK08 is primarily being investigated for the treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D), with a Phase III clinical trial underway. The company is also exploring SK08's efficacy in combination with PD-1 inhibitors for advanced solid tumors and for treating mild to moderate ulcerative colitis. Another significant pipeline candidate is SK10, an inactivated version of *Bacteroides fragilis*, which has completed a Phase 1 clinical trial in the U.S. for treating chemotherapy-induced diarrhea.
Since its inception, the company has secured significant funding to advance its clinical pipeline. It has completed multiple financing rounds, including a Series C in March 2024, raising a total of over $45 million from investors such as SDIC Venture Capital, Guangdong Investment, and KIP Capital. Headquartered in Guangzhou, the company has a research and development center and two GMP-standard pilot production workshops to support its clinical and future commercial activities. The company is led by CEO Ye Wang and Chairman Xiaohui Wang.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Guangzhou, China
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 53.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2024 | $14M | $55M | Guangdong Technology Financial Group · Airui Investment | ↗ |
| SERIES BOther financing | Jul 2022 | $15M | $60M | SDIC Venture Capital · Helichuangxing Group · GDD Fund | ↗ |
Growth signals
Latest recorded traffic for Guangzhou Zhiyi Biotechnology is 680 monthly website visits, up 277.8% over the last three months. Guangzhou Zhiyi Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Guangzhou Zhiyi Biotechnology in the Guangzhou ecosystem
The Guangzhou Zhiyi Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
- HCHejun Capital
Series A3 investors entered at this stage
SDIC Venture Capital- HGHelichuangxing Group
- GFGDD Fund
Series B and later2 investors entered at this stage
Guangdong Technology Financial Group- AIAirui Investment
Other known investors1 additional known investor
- SUSouthern Medical University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Guangzhou Zhiyi Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Guangzhou Zhiyi Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








